163 related articles for article (PubMed ID: 32731733)
21. Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: a randomized placebo-controlled trial.
Santamaria F; Montella S; Stocchero M; Pirillo P; Bozzetto S; Giordano G; Poeta M; Baraldi E
Pulm Pharmacol Ther; 2019 Oct; 58():101818. PubMed ID: 31302340
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of pidotimod in combination with bacterial lysates in the treatment of the pfapa (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) syndrome].
Buongiorno A; Pierossi N
Minerva Pediatr; 2015 Jun; 67(3):219-26. PubMed ID: 25941128
[TBL] [Abstract][Full Text] [Related]
23. Effects of Pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study.
Valentini D; Di Camillo C; Mirante N; Marcellini V; Carsetti R; Villani A
Ital J Pediatr; 2020 Mar; 46(1):31. PubMed ID: 32164747
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: a multicentre study.
Namazova-Baranova LS; Alekseeva AA; Kharit SM; Kozhevnikova TN; Taranushenko TE; Tuzankina IA; Scarci F
Int J Immunopathol Pharmacol; 2014; 27(3):413-9. PubMed ID: 25280032
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia.
Esposito S; Garziano M; Rainone V; Trabattoni D; Biasin M; Senatore L; Marchisio P; Rossi M; Principi N; Clerici M
J Transl Med; 2015 Sep; 13():288. PubMed ID: 26335787
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy.
Trabattoni D; Clerici M; Centanni S; Mantero M; Garziano M; Blasi F
Pulm Pharmacol Ther; 2017 Jun; 44():24-29. PubMed ID: 28302543
[TBL] [Abstract][Full Text] [Related]
27. [Stimulation of B-cell immunity in the nude mice by pidotimod: immunohistochemical stucy of various lymphoid organs].
Vacca A; Di Stefano R; Caloro D; Ranieri G; Dammacco F
Drugs Exp Clin Res; 1993; 19 Suppl():23-6. PubMed ID: 8625779
[No Abstract] [Full Text] [Related]
28. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders.
Hait EJ; McDonald DR
Clin Rev Allergy Immunol; 2019 Oct; 57(2):213-225. PubMed ID: 30206783
[TBL] [Abstract][Full Text] [Related]
29. Probiotics: Myths or facts about their role in allergy prevention.
Krzych-Fałta E; Furmańczyk K; Tomaszewska A; Olejniczak D; Samoliński B; Samolińska-Zawisza U
Adv Clin Exp Med; 2018 Jan; 27(1):119-124. PubMed ID: 29521052
[TBL] [Abstract][Full Text] [Related]
30. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials.
Niu H; Wang R; Jia YT; Cai Y
Int Immunopharmacol; 2019 Feb; 67():35-45. PubMed ID: 30530167
[TBL] [Abstract][Full Text] [Related]
31. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.
Giagulli C; Noerder M; Avolio M; Becker PD; Fiorentini S; Guzman CA; Caruso A
Int Immunopharmacol; 2009 Nov; 9(12):1366-73. PubMed ID: 19712757
[TBL] [Abstract][Full Text] [Related]
32. [Pidotimod, a new biological response modifier, is able to partially prevent immune response changes related to surgical stress].
Pasqui AL; Bruni F; Di Renzo M; Saletti M; Bova G; Gotti G; Auteri A
Drugs Exp Clin Res; 1993; 19 Suppl():45-53. PubMed ID: 8625782
[No Abstract] [Full Text] [Related]
33. Ex vivo evaluation of Pidotimod effect on immune response.
Pugliese A; Marinelli L; Forno B; Pollono AM; Uslenghi C; Girardello R
Pharmacol Res; 1992 Sep; 26 Suppl 2():178-9. PubMed ID: 1409298
[No Abstract] [Full Text] [Related]
34. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice.
Tauber M; Apoil PA; Richet C; Laurent J; De Bonnecaze G; Mouchon E; Cassagne M; Marguery MC; Hegazy S; Konstantinou MP; Severino M; Uthurriague C; Giordano-Labadie F; Didier A; Paul C
Br J Dermatol; 2019 Jun; 180(6):1551-1552. PubMed ID: 30633329
[No Abstract] [Full Text] [Related]
35. Effect of Pidotimod, a new immunostimulating agent, on some aspects of immune response. In vitro study.
Auteri A; Pasqui AL; Bruni F; Saletti M; Di Renzo M; Bova G
Pharmacol Res; 1992 Sep; 26 Suppl 2():196-7. PubMed ID: 1409308
[No Abstract] [Full Text] [Related]
36. Pidotimod and Immunological Activation in Individuals Infected with HIV.
Ucciferri C; Falasca K; Reale M; Tamburro M; Auricchio A; Vignale F; Vecchiet J
Curr HIV Res; 2021; 19(3):260-268. PubMed ID: 33430735
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and preliminary pharmacological evaluation of pidotimod, its enantiomer, diastereomers and carboxamido derivatives.
Magni A; Signorelli G; Bocchiola G
Arzneimittelforschung; 1994 Dec; 44(12A):1402-4. PubMed ID: 7857331
[TBL] [Abstract][Full Text] [Related]
38. Pidotimod in the management of vulvar papillomatosis: double-blind clinical trial versus placebo.
Guerra B; Perino A; Polatti F; Scala M
Am J Ther; 1998 May; 5(3):147-52. PubMed ID: 10099052
[TBL] [Abstract][Full Text] [Related]
39. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG
J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481
[TBL] [Abstract][Full Text] [Related]
40. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
Front Immunol; 2020; 11():599083. PubMed ID: 33281825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
